INFUSE Bone Graft for TLIF receives eligibility for Medicare New Technology Add-on Payment, Advancing Reimbursement Support for Hospitals and Spine Surgeons

GALWAY, Ireland, September 2, 2026 - Medtronic (NYSE: MDT), a global leader in healthcare technology announced that the Centers for Medicare and Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for INFUSE™ Bone Graft for TLIF, effective October 1, 2026.

NTAP is a Medicare Fee For Service inpatient reimbursement mechanism designed to help support hospital adoption of qualifying new technologies during the period before standard payment rates are updated. By providing additional reimbursement for certain cases when the cost of a new technology exceeds the standard payment amount, NTAP can help reduce hospital financial barriers to early adoption and support patient access.

"This NTAP reflects the clinical value of INFUSE™ Bone Graft for TLIF and reinforces the importance of reimbursement support in helping hospitals adopt innovative technologies," said Dave Breiter, vice president of Clinical, Medical, Regulatory Affairs and Health Economics for the Cranial & Spinal Technologies business. "For surgeons, hospitals, and patients, this milestone helps strengthen access to a proven biologic option for spine procedures while supporting the realities of inpatient care delivery."

INFUSE™ bone graft is the first and only growth factor technology approved for use in spine fusion procedures. Earlier this year, Infuse™ bone graft received FDA premarket approval for TLIF following Breakthrough Device Designation (BDD) and a prioritized review timeline, underscoring the strength of the clinical evidence supporting its use. NTAP builds on that momentum by helping support hospital access to this important innovation.

The NTAP program is particularly relevant for hospital administrators and revenue cycle leaders, who evaluate not only clinical value, but also the reimbursement environment that can influence investments in new technologies.

This milestone underscores Medtronic's commitment to advancing clinically meaningful innovation and helping expand access to important technologies in the hospital setting.

About NTAP
NTAP, or New Technology Add-on Payment, is a Medicare Fee For Service reimbursement mechanism for qualifying technologies used in the inpatient hospital setting. It is intended to help bridge the gap between the introduction of a new technology and the time when hospital payment rates are recalibrated to reflect its cost.

For more information about the NTAP designation for Infuse™ bone graft for TLIF: medtronic.com/SpineLine

About the Cranial & Spinal Technologies Business at Medtronic
As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries.

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Christine Stewart
Public Relations
+1-269-377-2557

Ingrid Goldberg
Investor Relations
+1-763-505-2696